Drug research

AD109

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Study That Tests AD109 in Patients Taking GLP-1 DrugsNCT06400615	Apnimed	Phase 2	Completed	2024-12-26Actual
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)NCT05813275	Apnimed	Phase 3	Completed	2025-03-10Actual
Parallel Arm Trial of AD109 and AD504 In Patients With OSANCT05071612	Apnimed	Phase 2	Completed	2022-07-20Actual
Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)NCT05811247	Apnimed	Phase 3	Completed	2025-05-07Actual

ApnimedCompletedPrimary completion: 2024-12-26 · Actual

Trial details

ApnimedCompletedPrimary completion: 2025-03-10 · Actual

Trial details

ApnimedCompletedPrimary completion: 2022-07-20 · Actual

Trial details

ApnimedCompletedPrimary completion: 2025-05-07 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.